13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001943819
Total reported value
$300.5M
$300.5M
10 檔
58.4%
According to the latest 13F quarterly dataset, Valence8 US LP managed an equity portfolio of $300.5M at the end of Q4 2024, spanning 10 distinct U.S. exchange-listed positions.
In Q4 2024, Valence8 US LP adopted a defensive or profit-taking posture, trimming 5 positions and completely liquidating 40 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | QUAL | Ishares Msci USA Quality Fac | ETF-Other | 27.96% | +7.47% | -3.13% | |
| 2 | QQQ | Invesco Qqq Trust Series 1 | ETF-Tech | 20.57% | +5.34% | -4.94% | |
| 3 | IQLT | Ishares Msci International Q | ETF-Other | 17.66% | -4.97% | -3.49% | |
| 4 | EFV | Ishares Msci Eafe Value ETF | ETF-Other | 10.19% | -2.98% | +1.27% | |
| 5 | VTV | Vanguard Value ETF | ETF-Other | 7.92% | +2.89% | +0.79% | |
| 6 | XLP | Ss Consumer Staples Sel Sect | ETF-Other | 6.27% | +2.69% | +0.54% | |
| 7 | IGV | Ishares Expanded Tech-softwa | ETF-Tech | 3.75% | — | — | |
| 8 | EWU | Ishares Msci United Kingdom | ETF-Other | 1.90% | -0.05% | -44.26% | |
| 9 | XLU | St Sr Utl Sl Se Spdr Etf-usd | ETF-Other | 1.90% | +1.07% | +0.59% | |
| 10 | EWJ | Ishares Msci Japan ETF | ETF-Other | 1.89% | — | -46.01% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IGV | Ishares Expanded Tech-softwa | +3.8% | NEW | New buy |
| 2 | QUAL | Ishares Msci USA Quality Fac | +2.9% | -3.13% | Trim |
| 3 | QQQ | Invesco Qqq Trust Series 1 | +2.7% | -4.94% | Trim |
| 4 | VTV | Vanguard Value ETF | +0.9% | +0.79% | Add |
| 5 | EFV | Ishares Msci Eafe Value ETF | +0.7% | +1.27% | Add |
| 6 | XLP | Ss Consumer Staples Sel Sect | +0.6% | +0.54% | Add |
| 7 | XLU | St Sr Utl Sl Se Spdr Etf-usd | +0.2% | +0.59% | Add |
| 8 | IQLT | Ishares Msci International Q | — | -3.49% | Trim |
| 9 | ✓ | Zura Bio LTD | 0% | EXIT | Sold out |
| 10 | VTGN | Vistagen Therapeutics Inc | 0% | EXIT | Sold out |
| 11 | BCRX | Biocryst Pharmaceuticals Inc | 0% | EXIT | Sold out |
| 12 | ERAS | Erasca Inc | -0.1% | EXIT | Sold out |
| 13 | IOVA | Iovance Biotherapeutics Inc | -0.1% | EXIT | Sold out |
| 14 | SLDB | Solid Biosciences Inc | -0.1% | EXIT | Sold out |
| 15 | ZVRA | Zevra Therapeutics Inc | -0.1% | EXIT | Sold out |
| 16 | APLT | Applied Therapeutics Inc | -0.1% | EXIT | Sold out |
| 17 | RLAY | Relay Therapeutics Inc | -0.1% | EXIT | Sold out |
| 18 | CLDX | Celldex Therapeutics Inc | -0.1% | EXIT | Sold out |
| 19 | ENTA | Enanta Pharmaceuticals Inc | -0.1% | EXIT | Sold out |
| 20 | VIR | Vir Biotechnology Inc | -0.1% | EXIT | Sold out |
| 21 | 2655787D | Blueprint Medicines CORP | -0.1% | EXIT | Sold out |
| 22 | MRNA | Moderna Inc | -0.1% | EXIT | Sold out |
| 23 | NTLA | Intellia Therapeutics Inc | -0.1% | EXIT | Sold out |
| 24 | VRDN | Viridian Therapeutics Inc | -0.1% | EXIT | Sold out |
| 25 | PCVX | Vaxcyte Inc | -0.1% | EXIT | Sold out |
| 26 | TYRA | Tyra Biosciences Inc | -0.1% | EXIT | Sold out |
| 27 | APGE | Apogee Therapeutics Inc | -0.1% | EXIT | Sold out |
| 28 | ALT | Altimmune Inc | -0.1% | EXIT | Sold out |
| 29 | ✓ | Avadel Pharmaceuticals PLC ADR | -0.1% | EXIT | Sold out |
| 30 | CRNX | Crinetics Pharmaceuticals In | -0.1% | EXIT | Sold out |
| 31 | APLSUSD | Apellis Pharmaceuticals Inc | -0.2% | EXIT | Sold out |
| 32 | NUVL | Nuvalent Inc-a | -0.2% | EXIT | Sold out |
| 33 | FLNA | Filana Therapeutics Inc | -0.2% | EXIT | Sold out |
| 34 | KROS | Keros Therapeutics Inc | -0.2% | EXIT | Sold out |
| 35 | NVO | Novo-nordisk A/s-spons Adr | -0.2% | EXIT | Sold out |
| 36 | JANX | Janux Therapeutics Inc | -0.2% | EXIT | Sold out |
| 37 | ARGX | Argenx Se - Adr | -0.2% | EXIT | Sold out |
| 38 | INDV | Indivior Pharmaceuticals, Inc. | -0.2% | EXIT | Sold out |
| 39 | LLY | Eli Lilly & Co | -0.2% | EXIT | Sold out |
| 40 | RARE | Ultragenyx Pharmaceutical In | -0.3% | EXIT | Sold out |
| 41 | CRSP | CRISPR Therapeutics AG | -0.3% | EXIT | Sold out |
| 42 | ASND | Ascendis Pharma A/S | -0.3% | EXIT | Sold out |
| 43 | BMY | Bristol-myers Squibb Co | -0.4% | EXIT | Sold out |
| 44 | JAZZ | Jazz Pharmaceuticals plc | -0.4% | EXIT | Sold out |
| 45 | INSM | Insmed Inc | -0.4% | EXIT | Sold out |
| 46 | SLNOEUR | Soleno Therapeutics Inc | -0.5% | EXIT | Sold out |
| 47 | AMGN | Amgen Inc | -0.5% | EXIT | Sold out |
| 48 | EWJ | Ishares Msci Japan ETF | -1.3% | -46.01% | Trim |
| 49 | EWU | Ishares Msci United Kingdom | -1.4% | -44.26% | Trim |
| 50 | AZNN | Astrazeneca Plc-spons Adr | -2.1% | EXIT | Sold out |
According to official SEC Form 13F filings, Valence8 US LP reported a total U.S. public equity portfolio value of $300.5M across 10 disclosed positions in Q4 2024.
During Q4 2024, Valence8 US LP's top holdings by market value included QUAL (28.0%)、QQQ (20.6%)、IQLT (17.7%). The largest single position, QUAL, represented 28.0% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including QUAL, QQQ, IQLT) accounted for 58.4% of total reported equity market value during Q4 2024.
Top New Position Initiated
IGV
市值: $7.8M
Top Position Liquidated / Trimmed
AZNN
前期市值: $5.0M
In Q4 2024, Valence8 US LP made 50 total portfolio adjustments, initiating 1 new buys, adding to 4 positions, trimming 5 holdings, and fully liquidating 40 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.